Category Archives: Emerging Markets

UN Pact Scuttles Anti-Vaccine Provision

By Jill Wechsler | Published: January 24, 2013
A new international agreement to reduce mercury contamination of air and water was recently adopted by 140 countries, without a proposal that threatened to limit access to vaccines in much of the world. The credit goes to public health authorities and medical experts who challenged a provision blocking production of vaccines with the preservative thimerosal, [...]
Also posted in FDA, Global, Legal, Market Access, Patient Communication, Safety, healthcare | Tagged , , , , , , | 1 Comment

Pharma's Promotional Spend: What's the Right Target?

By Clark Herman | Published: January 17, 2013
Global consultancy Cegedim has released its latest survey on how and where big Pharma puts its promotional dollar. Pharmaceutical Promotional Spend: Global Trends reports that spending in emerging markets significantly increased last year, while Europe and US declined slightly.  Although overall promotion spending remained flat worldwide at $90 billion, the US still accounts for the [...]
Also posted in Advertising, Europe, Global, Marketing, Meetings, Sales, Strategy, Technology, social media | Tagged , , , , , | Leave a comment

R&D Trends for 2013: Data Trims, Partnerships, and Emerging Global Players

By Clark Herman | Published: January 14, 2013
The Tufts Center for the Study of Drug Development (CSDD) sees two key trends as increasingly important for pharmaceutical companies to maintain success: eliminating the bane of extraneous data and fostering collaborations with academia and multi-company consortia both as measures of reducing costs and remaining competitive by more quickly and effectively guiding medicines to market. [...]
Also posted in IP, R&D, Strategy | Tagged , , | 1 Comment

Pharma 2012 Layoffs

By Reid Paul | Published: January 9, 2013
brightcove.createExperiences();
Also posted in Europe, Global, Manufacturing, Marketing, News, People, R&D, Sales, Strategy, Video | Leave a comment

SEC Charges Lilly with Corruption Abroad: A Taste of Fines to Come

By Clark Herman | Published: December 21, 2012
The Securities and Exchange Commission filed charges on Eli Lilly and Co. yesterday for violations of the Foreign Corrupt Practices Act (FCPA) that allege the drug maker’s subsidiaries overseas bribed foreign officials in Russia, China, Brazil and Poland. The settlement totaled $29 million after an investigation of activities reaching as far back as 1994, assessed [...]
Also posted in Global, Legal, Regulatory | Tagged | 1 Comment